BMY vs NVO

Bristol Myers Squibb and Novo Nordisk A/S, both Healthcare

Novo Nordisk A/S is the larger company at $171B against $117B. Over the past year BMY returned +32% against -34% for NVO. The RyuScore puts NVO ahead, 88 against 54 out of 100.

Bristol Myers Squibb and Novo Nordisk A/S compared on valuation, return and the RyuScore
Figure	BMY	NVO
Last close	$57.49	$38.58
Market cap	$117B	$171B
Trailing P/Elower is cheaper for the same earnings, not automatically better	12.7	n/a
Dividend yield	4.3%	n/a
1-year return	+32%	-34%
5-year return	+12%	-16%
RyuScoresector-relative, 1–10	54/100	88/100

Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.

Bristol Myers Squibb

Revenue of $13B in Q2 2026, net income $3.3B. Its largest reported line is Eliquis, 33% of the disclosed total.

BMY overview revenue and segments valuation

Novo Nordisk A/S

NVO overview revenue and segments valuation

Open these two in the interactive comparison to add more names, change the period or see the correlation.